| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a22000004a 4500 |
| 001 |
in00004504792 |
| 005 |
20191203131622.0 |
| 008 |
060525s2007 fluaf b 001 0 eng |
| 010 |
|
|
|a 2006045588
|
| 015 |
|
|
|a GBA659285
|2 bnb
|
| 016 |
7 |
|
|a 013504892
|2 Uk
|
| 020 |
|
|
|a 0849337747
|
| 020 |
|
|
|a 1420005405
|
| 020 |
|
|
|a 9781420005400
|
| 020 |
|
|
|a 9780849337741
|
| 029 |
1 |
|
|a YDXCP
|b 2414331
|
| 035 |
|
|
|a (OCoLC)ocm70046055
|
| 035 |
|
|
|z (UtOrBLW)41542
|
| 035 |
|
|
|a 59379
|
| 040 |
|
|
|a DLC
|c DLC
|d BAKER
|d UKM
|d C#P
|d YDX
|d BTCTA
|d YDXCP
|d OCL
|d TMV
|d UtOrBLW
|
| 042 |
|
|
|a pcc
|
| 049 |
|
|
|a TMVM
|c 1
|
| 050 |
0 |
0 |
|a QP609.C93
|b I54 2007
|
| 060 |
|
4 |
|a QZ 267
|b I55 2007
|
| 082 |
0 |
0 |
|a 616.99/407
|2 22
|
| 245 |
0 |
0 |
|a Inhibitors of cyclin-dependent kinases as anti-tumor agents /
|c edited by Paul J. Smith, Eddy W. Yue.
|
| 264 |
|
1 |
|a Boca Raton :
|b CRC/Taylor & Francis,
|c [2007]
|
| 264 |
|
4 |
|c ©2007
|
| 300 |
|
|
|a 448 pages, 8 unnumbered pages of plates :
|b illustrations (some color) ;
|c 25 cm.
|
| 336 |
|
|
|a text
|2 rdacontent
|b txt
|
| 337 |
|
|
|a unmediated
|2 rdamedia
|
| 338 |
|
|
|a volume
|2 rdacarrier
|b nc
|
| 490 |
1 |
|
|a CRC enzyme inhibitors series
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Cell cycle dynamics and the challenges for CDK targeting -- Functional regulation of CIP/KIP CDK inhibitors -- Mouse models to study the in vivo function of cyclin-dependent kinases in normal homeostasis and tumor development -- Cyclin-dependent kinase inhibitors and vascular disease -- Evaluation of CDK inhibitor selectivity : from affinity chromotography to yeast genetics -- Development of CDK inhibitors as anticancer agents : from rational design to CDK4-specific inhibition -- Three-dimensional structures of cyclin-dependent kinases and their inhibitor complexes -- Cyclin-dependent kinase small molecular modulators for cancer therapy -- (R)-roscovitine (CYC202, Seliciclib) -- Development, selectivity, and application of paullones, a family of CDK inhibitors -- Discovery of BMS-387032, a potent cyclin-dependent kinase inhibitor in clinical development -- Oxindole inhibitors of cyclin-dependent kinases as anti-tumor agents -- Indenopyrazoles as cyclin-dependent kinase inhibitors -- Development of insolocarbazoles as cyclin D1/CDK4 inhibitors -- Pyrazoles as efficient adenine-mimetic heterocycles for the discovery of CDK inhibitors -- Pyrazolo[3,4-d]pyrimidie-4-ones : exploring the structural determinants of potency and selectivity in cyclin-dependent kinase inhibition -- Cyclin-dependent kinase inhibitors and combination therapy : experimental and clinical status -- CDK inhibitors as anticancer agsnts : perspectives for the future
|
| 650 |
|
0 |
|a Cyclin-dependent kinases
|x Inhibitors.
|
| 650 |
|
0 |
|a Cyclin-dependent kinases
|x Inhibitors
|x Therapeutic use
|x Testing.
|
| 650 |
|
0 |
|a Cancer
|x Chemotherapy.
|
| 650 |
|
2 |
|a Cyclin-Dependent Kinase Inhibitor Proteins
|x therapeutic use.
|
| 650 |
|
2 |
|a Antineoplastic Agents
|x therapeutic use.
|
| 700 |
1 |
|
|a Smith, Paul J.
|q (Paul James),
|d 1953-
|
| 700 |
1 |
|
|a Yue, Eddy W.
|
| 830 |
|
0 |
|a CRC enzyme inhibitors series.
|
| 999 |
|
|
|a MARS
|
| 999 |
f |
f |
|s f6522a4d-5437-3d00-ad26-de7055f66c4a
|i 5833618b-4681-3d7c-ad60-1a2604ea77f3
|t 0
|
| 952 |
f |
f |
|p ric
|a Texas A&M University
|b Rellis Campus
|c Joint Library Facility
|d Remote Storage
|t 0
|e QZ 267 I55 2007
|h National Library of Medicine classification
|i unmediated -- volume
|m 3238901926088
|
| 998 |
f |
f |
|a QZ 267 I55 2007
|t 0
|l Remote Storage
|